Published in Cancer Immunol Immunother on October 27, 2005
Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers. Clin Cancer Res (2008) 1.32
Establishment of transplantable porcine tumor cell lines derived from MHC-inbred miniature swine. Blood (2007) 1.14
Immunity and immune suppression in human ovarian cancer. Immunotherapy (2011) 1.07
Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother (2010) 0.88
Retracted Targeted immune therapy of ovarian cancer. Cancer Metastasis Rev (2015) 0.84
Generation of functional CD8+ T cells by human dendritic cells expressing glypican-3 epitopes. J Exp Clin Cancer Res (2010) 0.81
Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity. Clin Dev Immunol (2010) 0.79
Magnetic resonance imaging-guided adoptive cellular immunotherapy of central nervous system tumors with a T1 contrast agent. Magn Reson Med (2009) 0.78
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy. Immunotargets Ther (2014) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell (2009) 2.84
Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. J Immunother (2002) 2.65
Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol (2011) 2.52
Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. Clin Cancer Res (2011) 2.44
Aging of blood can be tracked by DNA methylation changes at just three CpG sites. Genome Biol (2014) 2.40
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Impact of cryopreservation on tetramer, cytokine flow cytometry, and ELISPOT. BMC Immunol (2005) 2.31
GM foods and the misperception of risk perception. Risk Anal (2004) 2.20
A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77
Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol (2006) 1.65
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunol (2008) 1.60
Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res (2008) 1.59
Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force. J Transl Med (2010) 1.57
Endoscopic treatment of arachnoid cysts: a detailed account of surgical techniques and results. Neurosurgery (2010) 1.57
Modeling of asymmetric cell division in hematopoietic stem cells--regulation of self-renewal is essential for efficient repopulation. Stem Cells Dev (2009) 1.57
Epigenetic-aging-signature to determine age in different tissues. Aging (Albany NY) (2011) 1.55
Technical aids in the diagnosis of brain death: a comparison of SEP, AEP, EEG, TCD and CT angiography. Dtsch Arztebl Int (2012) 1.53
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol (2006) 1.53
Specific age-associated DNA methylation changes in human dermal fibroblasts. PLoS One (2011) 1.51
Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res (2002) 1.51
Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res (2004) 1.49
CD4 regulatory T cells in human cancer pathogenesis. Cancer Immunol Immunother (2006) 1.47
Endoscopic transventricular third ventriculostomy through the lamina terminalis. J Neurosurg (2010) 1.44
Calcification or dedifferentiation: requirement to lock mesenchymal stem cells in a desired differentiation stage. J Cell Physiol (2009) 1.42
Mesenchymal stem cells and cardiac repair. J Cell Mol Med (2008) 1.37
Pluripotent stem cells escape from senescence-associated DNA methylation changes. Genome Res (2012) 1.32
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol (2006) 1.31
TNM staging in colorectal cancer: T is for T cell and M is for memory. J Clin Oncol (2011) 1.30
Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade. J Immunol (2010) 1.26
VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res (2011) 1.25
Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells. J Cell Mol Med (2009) 1.25
Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer. Cancer Res (2008) 1.24
Endoscopic third ventriculostomy in infants of less than 1 year of age: which factors influence the outcome? Childs Nerv Syst (2004) 1.23
Impact of individual platelet lysates on isolation and growth of human mesenchymal stromal cells. Cytotherapy (2010) 1.23
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens. Cancer Res (2006) 1.22
Monitoring of cellular senescence by DNA-methylation at specific CpG sites. Aging Cell (2012) 1.22
The endogenous danger signal, crystalline uric acid, signals for enhanced antibody immunity. Blood (2007) 1.21
Polysaccharide krestin is a novel TLR2 agonist that mediates inhibition of tumor growth via stimulation of CD8 T cells and NK cells. Clin Cancer Res (2010) 1.20
Immunization of cancer patients with HER-2/neu-derived peptides demonstrating high-affinity binding to multiple class II alleles. Clin Cancer Res (2003) 1.19
Donor age of human platelet lysate affects proliferation and differentiation of mesenchymal stem cells. PLoS One (2012) 1.18
MicroRNAs are shaping the hematopoietic landscape. Haematologica (2011) 1.17
Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplant (2011) 1.17
Population dynamics of mesenchymal stromal cells during culture expansion. Cytotherapy (2011) 1.16
N-cadherin is expressed on human hematopoietic progenitor cells and mediates interaction with human mesenchymal stromal cells. Stem Cell Res (2010) 1.16
Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther (2008) 1.15
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 1.15
Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res (2005) 1.14
Chitosan-alginate 3D scaffolds as a mimic of the glioma tumor microenvironment. Biomaterials (2010) 1.14
Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature. J Immunol (2007) 1.14
Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica (2010) 1.14
Stem cells and ageing. The potential of stem cells to overcome age-related deteriorations of the body in regenerative medicine. EMBO Rep (2005) 1.13
Satellite-based terrestrial production efficiency modeling. Carbon Balance Manag (2009) 1.11
Two-photon absorption and self-phase modulation measurements with shaped femtosecond laser pulses. Opt Lett (2005) 1.10
Induced pluripotent mesenchymal stromal cell clones retain donor-derived differences in DNA methylation profiles. Mol Ther (2012) 1.07
Tumor cells transduced with the MHC class II Transactivator and CD80 activate tumor-specific CD4+ T cells whether or not they are silenced for invariant chain. Cancer Res (2006) 1.04
ELISpot for measuring human immune responses to vaccines. Expert Rev Vaccines (2011) 1.04
Hematopoietic stem and progenitor cells acquire distinct DNA-hypermethylation during in vitro culture. Sci Rep (2013) 1.04
Conflicts of interest in translational research. J Transl Med (2004) 1.03
Targeting of primary breast cancers and metastases in a transgenic mouse model using rationally designed multifunctional SPIONs. ACS Nano (2012) 1.03
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med (2011) 1.02
Adipogenic differentiation of human mesenchymal stromal cells is down-regulated by microRNA-369-5p and up-regulated by microRNA-371. J Cell Physiol (2011) 1.01
Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res (2007) 1.01
TLR2 agonist PSK activates human NK cells and enhances the antitumor effect of HER2-targeted monoclonal antibody therapy. Clin Cancer Res (2011) 1.00
Translational Research Working Group developmental pathway for immune response modifiers. Clin Cancer Res (2008) 1.00
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase. Cancer Immunol Immunother (2010) 0.99
Modeling of replicative senescence in hematopoietic development. Aging (Albany NY) (2009) 0.99
Myosin motors at neuronal synapses: drivers of membrane transport and actin dynamics. Nat Rev Neurosci (2013) 0.97
Hypoxic/normoxic preconditioning increases endothelial differentiation potential of human bone marrow CD133+ cells. Tissue Eng Part C Methods (2010) 0.96
Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. J Neurooncol (2009) 0.96
Success and failure of endoscopic third ventriculostomy in young infants: are there different age distributions? Childs Nerv Syst (2006) 0.95
The beauty of asymmetry: asymmetric divisions and self-renewal in the haematopoietic system. Curr Opin Hematol (2007) 0.95
Emergence of immune escape variant of mammary tumors that has distinct proteomic profile and a reduced ability to induce "danger signals". Breast Cancer Res Treat (2005) 0.95
Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity. J Immunol Methods (2005) 0.95
Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest (2004) 0.95
3D co-culture of hematopoietic stem and progenitor cells and mesenchymal stem cells in collagen scaffolds as a model of the hematopoietic niche. Biomaterials (2011) 0.95
Expanding assessments of translational research programs: supplementing metrics with value judgments. Eval Health Prof (2013) 0.94
Unilateral multilevel interlaminar fenestration instead of laminectomy or hemilaminectomy: an alternative surgical approach to intraspinal space-occupying lesions. Technical note. J Neurosurg Spine (2007) 0.94
Consequences of media information uptake and deliberation: focus groups' symbolic coping with synthetic biology. Public Underst Sci (2012) 0.94
Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Exp Hematol (2011) 0.94
The epigenetic tracks of aging. Biol Chem (2014) 0.93
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol (2007) 0.93
The CXCR4 antagonist AMD3100 releases a subset of G-CSF-primed peripheral blood progenitor cells with specific gene expression characteristics. Exp Hematol (2006) 0.92
Acute anoxia stimulates proliferation in adult neural stem cells from the rat brain. Exp Brain Res (2008) 0.92
Human platelet lysate gel provides a novel three dimensional-matrix for enhanced culture expansion of mesenchymal stromal cells. Tissue Eng Part C Methods (2012) 0.92
The invisible arm of immunity in common cancer chemoprevention agents. Cancer Prev Res (Phila) (2013) 0.92
Phenotype and in vitro function of mature MDDC generated from cryopreserved PBMC of cancer patients are equivalent to those from healthy donors. J Immune Based Ther Vaccines (2007) 0.91
Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology (2011) 0.91
Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer. Radiat Oncol (2013) 0.91
Dendritic cell-activating vaccine adjuvants differ in the ability to elicit antitumor immunity due to an adjuvant-specific induction of immunosuppressive cells. Clin Cancer Res (2012) 0.91
Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother (2003) 0.89
Communicating Synthetic Biology: from the lab via the media to the broader public. Syst Synth Biol (2009) 0.89
Direct detection of carcinoembryonic antigen autoantibodies in clinical human serum samples using a surface plasmon resonance sensor. Colloids Surf B Biointerfaces (2008) 0.89
Evidence for a bipolar change in distortion product otoacoustic emissions during contralateral acoustic stimulation in humans. J Acoust Soc Am (2005) 0.89
Immunologic principles and immunotherapeutic approaches in ovarian cancer. Hematol Oncol Clin North Am (2003) 0.89
Standardized isolation of human mesenchymal stromal cells with red blood cell lysis. Methods Mol Biol (2011) 0.88